{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T14:18:54Z","timestamp":1781101134104,"version":"3.54.1"},"reference-count":65,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T00:00:00Z","timestamp":1613606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA138688"],"award-info":[{"award-number":["R01CA138688"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA187415"],"award-info":[{"award-number":["R01CA187415"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA233490"],"award-info":[{"award-number":["R01CA233490"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001695","name":"International Waldenstrom's Macroglobulinemia Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001695","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","award":["P50CA136411"],"award-info":[{"award-number":["P50CA136411"]}],"id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","award":["P50CA142509"],"award-info":[{"award-number":["P50CA142509"]}],"id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neoplasia"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.neo.2021.02.002","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T15:07:35Z","timestamp":1616080055000},"page":"361-374","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenstr\u00f6m macroglobulinemia"],"prefix":"10.1016","volume":"23","author":[{"given":"Yingjun","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasantha Lakshmi","family":"Gali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijun Y.","family":"Xu-Monette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dahlia","family":"Sano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheeba K.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna M.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9356-2154","authenticated-orcid":false,"given":"Feng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaosheng","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manman","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8788-7243","authenticated-orcid":false,"given":"Fredrick B.","family":"Hagemeister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Z.","family":"Orlowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Chulhee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken H.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.neo.2021.02.002_bib0001","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/sonc.2003.50082","article-title":"Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia","volume":"30","author":"Owen","year":"2003","journal-title":"Semin Oncol"},{"issue":"9","key":"10.1016\/j.neo.2021.02.002_bib0002","doi-asserted-by":"crossref","first-page":"824","DOI":"10.4065\/mcp.2010.0304","article-title":"Diagnosis and management of Waldenstr\u00f6m macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines","volume":"85","author":"Ansell","year":"2010","journal-title":"Mayo Clin Proc"},{"issue":"20","key":"10.1016\/j.neo.2021.02.002_bib0003","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.neo.2021.02.002_bib0004","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1001\/jamaoncol.2016.5763","article-title":"Diagnosis and Management of Waldenstr\u00f6m Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016","volume":"3","author":"Kapoor","year":"2017","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.neo.2021.02.002_bib0005","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1470-2045(16)30632-5","article-title":"Ibrutinib for patients with rituximab-refractory Waldenstrom's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"Lancet Oncol"},{"issue":"25","key":"10.1016\/j.neo.2021.02.002_bib0006","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1056\/NEJMoa1802917","article-title":"Phase 3 Trial of Ibrutinib plus Rituximab in Waldenstr\u00f6m's Macroglobulinemia","volume":"378","author":"Dimopoulos","year":"2018","journal-title":"New Engl J Med"},{"issue":"3","key":"10.1016\/j.neo.2021.02.002_bib0007","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1093\/annonc\/mdj111","article-title":"Characterization of familial Waldenstrom's macroglobulinemia","volume":"17","author":"Treon","year":"2006","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.neo.2021.02.002_bib0008","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11864-016-0391-7","article-title":"Waldenstrom Macroglobulinemia: Familial Predisposition and the Role of Genomics in Prognosis and Treatment Selection","volume":"17","author":"Kapoor","year":"2016","journal-title":"Curr Treat Options Oncol"},{"issue":"2","key":"10.1016\/j.neo.2021.02.002_bib0009","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/annonc\/mdr119","article-title":"Risk of second cancers in Waldenstrom macroglobulinemia","volume":"23","author":"Varettoni","year":"2012","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.neo.2021.02.002_bib0010","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1200710","article-title":"MYD88 L265P somatic mutation in Waldenstrom's macroglobulinemia","volume":"367","author":"Treon","year":"2012","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.neo.2021.02.002_bib0011","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1182\/blood-2013-09-525808","article-title":"The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis","volume":"123","author":"Hunter","year":"2014","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.neo.2021.02.002_bib0012","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1182\/blood-2014-05-573188","article-title":"Activation of lymphoma-associated MyD88 mutations via allostery-induced TIR-domain oligomerization","volume":"124","author":"Avbelj","year":"2014","journal-title":"Blood"},{"issue":"7332","key":"10.1016\/j.neo.2021.02.002_bib0013","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature09671","article-title":"Oncogenically active MYD88 mutations in human lymphoma","volume":"470","author":"Ngo","year":"2011","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.neo.2021.02.002_bib0014","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1182\/blood-2012-12-475111","article-title":"A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstrom macroglobulinemia","volume":"122","author":"Yang","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.neo.2021.02.002_bib0015","first-page":"66","article-title":"Imbruvica (Ibrutinib), First-in-Class Bruton's Tyrosine Kinase Inhibitor, Receives Expanded Indications for Patients with Relapsed Chronic Lymphocytic Leukemia","volume":"8","author":"Raedler","year":"2015","journal-title":"Am Health Drug Benefits"},{"issue":"15","key":"10.1016\/j.neo.2021.02.002_bib0016","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstrom's macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"New Engl J Med"},{"issue":"25","key":"10.1016\/j.neo.2021.02.002_bib0017","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1056\/NEJMoa1802917","article-title":"Phase 3 Trial of Ibrutinib plus Rituximab in Waldenstrom's Macroglobulinemia","volume":"378","author":"Dimopoulos","year":"2018","journal-title":"New Engl J Med"},{"issue":"6","key":"10.1016\/j.neo.2021.02.002_bib0018","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1158\/1078-0432.CCR-15-0646","article-title":"Genomic Landscape of CXCR4 Mutations in Waldenstrom Macroglobulinemia","volume":"22","author":"Poulain","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.neo.2021.02.002_bib0019","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/bjh.13200","article-title":"CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenstrom macroglobulinaemia cells","volume":"168","author":"Cao","year":"2015","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.neo.2021.02.002_bib0020","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1200\/JCO.2016.71.0814","article-title":"Genomics, Signaling, and Treatment of Waldenstrom Macroglobulinemia","volume":"35","author":"Hunter","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.neo.2021.02.002_bib0021","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/leu.2014.187","article-title":"The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia","volume":"29","author":"Cao","year":"2015","journal-title":"Leukemia"},{"issue":"27","key":"10.1016\/j.neo.2021.02.002_bib0022","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1200\/JCO.2018.78.6426","article-title":"Ibrutinib Monotherapy in Symptomatic, Treatment-Naive Patients With Waldenstrom Macroglobulinemia","volume":"36","author":"Treon","year":"2018","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.neo.2021.02.002_bib0023","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3324\/haematol.2012.070458","article-title":"Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenstrom's macroglobulinemia","volume":"98","author":"Nguyen-Khac","year":"2013","journal-title":"Haematologica"},{"issue":"20","key":"10.1016\/j.neo.2021.02.002_bib0024","doi-asserted-by":"crossref","first-page":"6325","DOI":"10.1158\/1078-0432.CCR-17-0007","article-title":"TP53 Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia","volume":"23","author":"Poulain","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.neo.2021.02.002_bib0025","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/bjh.15560","article-title":"TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenstrom macroglobulinaemia","volume":"184","author":"Gustine","year":"2019","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.neo.2021.02.002_bib0026","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1182\/blood.V100.8.2996","article-title":"Waldenstrom macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions","volume":"100","author":"Schop","year":"2002","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.neo.2021.02.002_bib0027","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1365-2141.2006.06389.x","article-title":"6q deletion in Waldenstrom macroglobulinemia is associated with features of adverse prognosis","volume":"136","author":"Ocio","year":"2007","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.neo.2021.02.002_bib0028","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3816\/CLM.2009.n.008","article-title":"Prognostic relevance of 6q deletion in Waldenstrom's macroglobulinemia: a multicenter study","volume":"9","author":"Chang","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"issue":"1","key":"10.1016\/j.neo.2021.02.002_bib0029","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cancergencyto.2005.04.013","article-title":"Deletion 6q is not a characteristic marker of nodal lymphoplasmacytic lymphoma","volume":"162","author":"Cook","year":"2005","journal-title":"Cancer Genet Cytogenet"},{"issue":"2","key":"10.1016\/j.neo.2021.02.002_bib0030","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S0165-4608(01)00577-5","article-title":"Trisomy 4 as the sole cytogenetic abnormality in a Waldenstrom macroglobulinemia","volume":"133","author":"Rivera","year":"2002","journal-title":"Cancer Genet Cytogenet"},{"issue":"8","key":"10.1016\/j.neo.2021.02.002_bib0031","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s00277-018-3311-z","article-title":"Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenstrom macroglobulinemia","volume":"97","author":"Paludo","year":"2018","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.neo.2021.02.002_bib0032","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/bjh.12102","article-title":"Response assessment in Waldenstrom macroglobulinaemia: update from the VIth International Workshop","volume":"160","author":"Owen","year":"2013","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.neo.2021.02.002_bib0033","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/bjh.15877","article-title":"Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments","volume":"185","author":"Hu","year":"2019","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.neo.2021.02.002_bib0034","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/cyto.b.21830","article-title":"Low-Grade Myelodysplastic Syndromes With Preserved CD34+ B-Cell Precursors (CD34+ Hematogones)","volume":"98","author":"Chen","year":"2020","journal-title":"Cytometry B Clin Cytom"},{"issue":"2","key":"10.1016\/j.neo.2021.02.002_bib0035","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3324\/haematol.2018.191148","article-title":"Persistent IDH1\/2 mutations in remission can predict relapse in patients with acute myeloid leukemia","volume":"104","author":"Ok","year":"2019","journal-title":"Haematologica"},{"issue":"18","key":"10.1016\/j.neo.2021.02.002_bib0036","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1182\/blood-2008-08-174961","article-title":"International prognostic scoring system for Waldenstrom macroglobulinemia","volume":"113","author":"Morel","year":"2009","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.neo.2021.02.002_bib0037","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood-2014-01-550905","article-title":"Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia","volume":"123","author":"Treon","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.neo.2021.02.002_bib0038","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/ajh.24955","article-title":"MYD88 mutation status does not impact overall survival in Waldenstrom macroglobulinemia","volume":"93","author":"Abeykoon","year":"2018","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.neo.2021.02.002_bib0039","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1158\/0008-5472.CAN-18-0781","article-title":"TLR Signaling Is Activated in Lymph Node-Resident CLL Cells and Is Only Partially Inhibited by Ibrutinib","volume":"79","author":"Dadashian","year":"2019","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.neo.2021.02.002_bib0040","doi-asserted-by":"crossref","first-page":"e565","DOI":"10.1038\/bcj.2017.40","article-title":"Waldenstrom macroglobulinemia cells devoid of BTK(C481S) or CXCR4(WHIM-like) mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment","volume":"7","author":"Paulus","year":"2017","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.neo.2021.02.002_bib0041","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/leu.2012.257","article-title":"IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenstrom macroglobulinemia\/lymphoplasmacytic lymphomas","volume":"27","author":"Gachard","year":"2013","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.neo.2021.02.002_bib0042","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1038\/leu.2013.62","article-title":"MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenstrom's macroglobulinemia","volume":"27","author":"Jimenez","year":"2013","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.neo.2021.02.002_bib0043","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1182\/blood-2012-09-454355","article-title":"MYD88 L265P in Waldenstrom macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction","volume":"121","author":"Xu","year":"2013","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.neo.2021.02.002_bib0044","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/bjh.16088","article-title":"CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenstrom macroglobulinaemia treated with ibrutinib","volume":"187","author":"Castillo","year":"2019","journal-title":"Br J Haematol"},{"issue":"21","key":"10.1016\/j.neo.2021.02.002_bib0045","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1182\/bloodadvances.2018022962","article-title":"Insights into the genomic landscape of MYD88 wild-type Waldenstrom macroglobulinemia","volume":"2","author":"Hunter","year":"2018","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.neo.2021.02.002_bib0046","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/bjh.13897","article-title":"Clonal architecture of CXCR4 WHIM-like mutations in Waldenstrom Macroglobulinaemia","volume":"172","author":"Xu","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.neo.2021.02.002_bib0047","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13045-015-0172-y","article-title":"Waldenstr\u00f6m macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis","volume":"8","author":"Cao","year":"2015","journal-title":"J Hematol Oncol"},{"issue":"19","key":"10.1016\/j.neo.2021.02.002_bib0048","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1182\/blood-2012-05-433334","article-title":"Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study","volume":"120","author":"Xu-Monette","year":"2012","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.neo.2021.02.002_bib0049","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1182\/blood-2015-11-680199","article-title":"Exome sequencing reveals recurrent germ line variants in patients with familial Waldenstrom macroglobulinemia","volume":"127","author":"Roccaro","year":"2016","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.neo.2021.02.002_bib0050","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1086\/507687","article-title":"Genomewide linkage screen for Waldenstrom macroglobulinemia susceptibility loci in high-risk families","volume":"79","author":"McMaster","year":"2006","journal-title":"Am J Hum Genet"},{"issue":"6","key":"10.1016\/j.neo.2021.02.002_bib0051","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.clml.2012.08.006","article-title":"Familial disease predisposition impacts treatment outcome in patients with Waldenstrom macroglobulinemia","volume":"12","author":"Treon","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"10.1016\/j.neo.2021.02.002_bib0052","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1038\/s41591-019-0566-4","article-title":"Stress-glucocorticoid-TSC22D3 axis compromises therapy-induced antitumor immunity","volume":"25","author":"Yang","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.neo.2021.02.002_bib0053","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.leukres.2016.05.003","article-title":"The ibrutinib B-cell proliferation inhibition is potentiated in vitro by dexamethasone: Application to chronic lymphocytic leukemia","volume":"47","author":"Manzoni","year":"2016","journal-title":"Leuk Res"},{"issue":"10","key":"10.1016\/j.neo.2021.02.002_bib0054","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.leukres.2012.07.005","article-title":"Rituximab in combination with high-dose dexamethasone for the treatment of relapsed\/refractory chronic lymphocytic leukemia","volume":"36","author":"Smolej","year":"2012","journal-title":"Leuk Res"},{"issue":"1","key":"10.1016\/j.neo.2021.02.002_bib0055","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s12185-019-02650-w","article-title":"Combined rituximab, bendamustine, and dexamethasone chemotherapy for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma: a multicenter phase II study","volume":"110","author":"Matsumoto","year":"2019","journal-title":"Int J Hematol"},{"issue":"3","key":"10.1016\/j.neo.2021.02.002_bib0056","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1365-2141.2011.08750.x","article-title":"Maintenance Rituximab is associated with improved clinical outcome in rituximab naive patients with Waldenstrom Macroglobulinaemia who respond to a rituximab-containing regimen","volume":"154","author":"Treon","year":"2011","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.neo.2021.02.002_bib0057","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/bjh.15148","article-title":"Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenstrom macroglobulinaemia","volume":"181","author":"Castillo","year":"2018","journal-title":"Br J Haematol"},{"issue":"Supplement_1","key":"10.1016\/j.neo.2021.02.002_bib0058","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1182\/blood-2019-121909","volume":"134","author":"Rummel","year":"2019","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.neo.2021.02.002_bib0059","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1182\/blood-2011-11-390989","article-title":"The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia","volume":"119","author":"de Rooij","year":"2012","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.neo.2021.02.002_bib0060","doi-asserted-by":"crossref","first-page":"3612","DOI":"10.1002\/cncr.29566","article-title":"Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens","volume":"121","author":"Thompson","year":"2015","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.neo.2021.02.002_bib0061","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/leu.2015.316","article-title":"BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia","volume":"30","author":"Chen","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.neo.2021.02.002_bib0062","article-title":"MYD88 L265P Elicits Mutation-specific Ubiquitination to Drive NF-\u03baB Activation and Lymphomagenesis","author":"Yu","year":"2020","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.neo.2021.02.002_bib0063","doi-asserted-by":"crossref","first-page":"6099","DOI":"10.1158\/1078-0432.CCR-16-0630","article-title":"Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenstrom Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status","volume":"22","author":"Cea","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.neo.2021.02.002_bib0064","doi-asserted-by":"crossref","first-page":"e492","DOI":"10.1038\/bcj.2016.93","article-title":"Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells","volume":"6","author":"Paulus","year":"2016","journal-title":"Blood Cancer J"},{"issue":"8","key":"10.1016\/j.neo.2021.02.002_bib0065","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1182\/blood-2017-08-797886","article-title":"Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia","volume":"131","author":"Chen","year":"2018","journal-title":"Blood"}],"container-title":["Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558621000087?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558621000087?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T13:08:26Z","timestamp":1761484106000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1476558621000087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":65,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S1476558621000087"],"URL":"https:\/\/doi.org\/10.1016\/j.neo.2021.02.002","relation":{},"ISSN":["1476-5586"],"issn-type":[{"value":"1476-5586","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenstr\u00f6m macroglobulinemia","name":"articletitle","label":"Article Title"},{"value":"Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neo.2021.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}